| Greasing the wheels of managing overweight and obesity with omega-3 fatty acids. | |
| | |
MedLine Citation:
|
PMID: 21981905 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The epidemic of overweight and obesity around the world and in the US is a major public health challenge, with 1.5 billion overweight and obese adults worldwide, and 68% of US adults and 31% of US children and adolescents overweight or obese. Obesity leads to serious health consequences, including an increased risk of type 2 diabetes mellitus and heart disease. Current preventive and medical treatments include lifestyle modification, medication, and bariatric surgery in extreme cases; however, they are either not very efficacious or are very expensive. Obesity is a complex condition involving the dysregulation of several organ systems and molecular pathways, including adipose tissue, the pancreas, the gastrointestinal tract, and the CNS. The role of the CNS in obesity is receiving more attention as obesity rates rise and treatments continue to fail. While the role of the hypothalamus in regulation of appetite and food intake has long been recognized, the roles of the CNS reward systems are beginning to be examined as the role of environmental influences on energy balance are explored. Omega-3 polyunsaturated fatty acids are essential nutrients that play a beneficial role in several disease processes due to their anti-inflammatory effects, modulation of lipids, and effects on the CNS. Omega-3 fatty acids, specifically EPA and DHA, have shown promising preliminary results in animal and human studies in the prevention and treatment of obesity. Given their effects on many of the pathways involved in obesity, and specifically in the endocannabinoid and mesocorticolimbic pathways, we hypothesize that EPA and DHA supplementation in populations can reduce the reward associated with food, thereby reduce appetite and food intake, and ultimately contribute to the prevention or reduction of obesity. If these fatty acids do harbor such potential, their supplementation in many parts of the world may hold great promise in reducing the global burden of obesity. |
| | |
Authors:
|
N Golub; D Geba; S A Mousa; G Williams; R C Block |
Related Documents
:
|
9632515 - Position of operant costs affects visits to resources by laboratory mice, mus musculus. 23391015 - Fermented milks and milk products as functional foods-a review. 21172395 - "watching a person who knows how to cook, you'll learn a lot". linked lives, cultural t... 23644955 - Self-reported food-related gastrointestinal symptoms in ibs are common and associated w... 18171175 - When dinner is dangerous: toxic frogs elicit species-specific responses from a generali... 941195 - Human urinary and liver conjugates of 17alpha-ethnylestradiol. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2011-10-06 |
Journal Detail:
|
Title: Medical hypotheses Volume: 77 ISSN: 1532-2777 ISO Abbreviation: Med. Hypotheses Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-11-07 Completed Date: 2012-03-06 Revised Date: 2013-04-26 |
Medline Journal Info:
|
Nlm Unique ID: 7505668 Medline TA: Med Hypotheses Country: United States |
Other Details:
|
Languages: eng Pagination: 1114-20 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
The University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Appetite Depressants
/
therapeutic use* Disease Management* Docosahexaenoic Acids Eating / drug effects* Eicosapentaenoic Acid Fatty Acids, Omega-3 / therapeutic use* Humans Models, Biological* Obesity / drug therapy* |
| Grant Support | |
ID/Acronym/Agency:
|
R21 HL102582-01/HL/NHLBI NIH HHS; R21 HL102582-02/HL/NHLBI NIH HHS; UL1 RR024160/RR/NCRR NIH HHS; UL1 RR024160/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Appetite Depressants; 0/Fatty Acids, Omega-3; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepatotoxicity and liver enzyme alteration in patients with immunobullous diseases receiving immunos...
Next Document: Joint hypermobility in children with idiopathic scoliosis: SOSORT award 2011 winner.